Jonathan Sjögren

TL;DR: It is concluded that EndoS2 is a unique endoglycosidase in serotype M49 of GAS and differs from EndoS of other GAS strains by targeting both IgG and AGP.

TL;DR: A wide range of IdeS-based applications are presented for improved characterization of originator, biosimilar and next generation antibody-based therapeutics, focused on critical quality attributes of the final antibody product as studied by IdeS fragmentation.

TL;DR: Saliva from patients with aphthous ulcers and Behçet disease prone to oral ulcers failed to induce NETosis, but for different reasons it demonstrated that disordered homeostasis in the oral cavity may result in deficient saliva-mediated NETosis.

TL;DR: A novel chemoenzymatic approach driven by a newly available O-protease and solid phase platform that enables the assignment of O-glycosylated peptides, N-glycan profile, sialyl O- glycopeptides linkage, and mapping of heterogeneous O- Glycosylation and should become an indispensable tool for investigations where O-behavioural modification is central.

TL;DR: It is concluded that EndoS and EndoS2 hydrolyze different glycoforms from the Fc-glycosylation site on therapeutic mAbs and that this can be used for rapid quantification of high mannose content.